Tue, May 27, 2025
[ Tue, May 27th 2025 ]: BBC
Carpet in the bathroom - yay or nay?
Mon, May 26, 2025
[ Mon, May 26th 2025 ]: Forbes
Is Science Slowing Down?
Sun, May 25, 2025
[ Sun, May 25th 2025 ]: BBC
Ready in 20: Tandoori hot naan pizza
Sat, May 24, 2025
Fri, May 23, 2025
Thu, May 22, 2025
[ Thu, May 22nd 2025 ]: BBC
Dan Biggar tests a smart rugby ball
Wed, May 21, 2025
[ Wed, May 21st 2025 ]: BBC
20 min meal: Brin's cumin beef
Tue, May 20, 2025
[ Tue, May 20th 2025 ]: 13abc
Moment of Science: Cicadas
Mon, May 19, 2025

When the FDA requires a large vaccine trial, who pays?

The article from STAT News dated May 20, 2025, discusses several key developments in the biotech industry. Pfizer has acquired Tourmaline Bio for $1.5 billion, aiming to bolster its immunology portfolio. Novavax is facing challenges with its Covid-19 vaccine, reporting a significant drop in sales and contemplating strategic alternatives. Prime Medicine has received FDA clearance for its first clinical trial using prime editing technology, marking a significant step in gene editing. Additionally, the FDA has approved a new CRISPR-based therapy for sickle cell disease, highlighting advancements in genetic treatments. The article also touches on the ongoing debate over vaccine mandates and the impact of recent court rulings on public health policies.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/05/20/biotech-news-pfizer-tourmaline-novavax-prime-crispr-fda-vaccines-the-readout/ ]